Travere Therapeutics

TVTX Rare disease Lead: Approved ★ Read the deep dive → 14 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

Campbell PSU grant corporate updateearly 2027Campbell PSU grant corporate update, early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

FILSPARI

sparsentan

Small Molecule Target: endothelin type A receptor, angiotensin II type 1 receptor, endothelin-1, angiotensin II

IgA Nephropathy Approved oral CSL Vifor Renalys Pharma · Japan & Asia NCT03762850
Focal Segmental Glomerulosclerosis Approved oral CSL Vifor Renalys Pharma · Japan & Asia NCT01613118

pegtibatinase

Protein Target: cystathionine beta-synthase

Homocystinuria Phase 3 NCT03406611

Thiola

Thiola EC · tiopronin

Small Molecule

Cystinuria Approved oral Mission Pharmacal

civorebrutinib

EVER001

Small Molecule Target: BTK

Primary Membranous Nephropathy Phase 2 Phase 1/2 trial oral Everest Medicines
Focal Segmental Glomerulosclerosis Preclinical oral Everest Medicines
Minimal Change Disease Preclinical oral Everest Medicines

Biotech Distilled coverage (14)

2026-10-02 UPDATE: Travere Therapeutics (TVTX) - The eGFR Slope Comes Back, Post Hoc ★ Distilled Pro
2026-09-24 UPDATE: Travere Therapeutics (TVTX) - The FSGS Patent Closes the Loop 🔒 Paid
2026-09-22 UPDATE: Travere Therapeutics (TVTX) - The CEO Who Built the FSGS Franchise Is Stepping Down 🔒 Paid
2026-08-05 UPDATE: Travere Therapeutics (TVTX) - The Blowout Quarter, and Two Things Buried in the 10-Q 🔒 Paid
2026-06-04 UPDATE: Travere Therapeutics (TVTX) - The DUPLEX Switch-Arm Data Answers the Question That Haunted the FSGS PDUFA
2026-06-02 UPDATE: Travere Therapeutics (TVTX) - The $112.5M Answer to the “What’s the Cash For” Question
2026-05-27 UPDATE: Travere Therapeutics (TVTX) - The 2030 Patent Cliff Just Got Pushed to 2037 🔒 Paid
2026-05-08 UPDATE: Travere Therapeutics (TVTX) - The Convert Math Prints, And It’s Better Than I Modeled 🔒 Paid
2026-05-06 UPDATE: Travere Therapeutics (TVTX) - The $400M Convert Refi Lands One Day After the Q1 Print 🔒 Paid
2026-05-04 UPDATE: Travere Therapeutics (TVTX) - The Profitability Inflection Arrives
2026-04-18 UPDATE: Travere Therapeutics (TVTX) - The FDA Folds, The Bulls Win, and FILSPARI Gets the FSGS Crown 🔒 Paid
2026-04-04 UPDATE: Travere Therapeutics (TVTX) - The C-Suite is Selling 12 Days Before the FDA Verdict 🔒 Paid
2026-02-21 UPDATE: Travere Therapeutics (TVTX) - Commercial Liftoff, CMC Recovery, and Why the Smart Money is Trimming 🔒 Paid
2026-02-06 Travere Therapeutics (TVTX): Scientific Deep Dive for Sparsentan, Pegtibatinase, and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.